Merck & Co., Inc.’s (MRK) “Overweight” Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald reiterated their overweight rating on shares of Merck & Co., Inc. (NYSE:MRKFree Report) in a research report sent to investors on Monday, Benzinga reports. They currently have a $135.00 price objective on the stock.

A number of other equities analysts have also commented on MRK. Truist Financial boosted their price target on shares of Merck & Co., Inc. from $122.00 to $139.00 and gave the company a buy rating in a research report on Friday, February 2nd. BMO Capital Markets upgraded shares of Merck & Co., Inc. from a market perform rating to an outperform rating and set a $132.00 price target on the stock in a research report on Friday, October 27th. TheStreet upgraded shares of Merck & Co., Inc. from a c+ rating to a b rating in a research report on Monday, November 27th. Wells Fargo & Company boosted their price target on shares of Merck & Co., Inc. from $125.00 to $130.00 and gave the stock an equal weight rating in a research note on Friday, February 2nd. Finally, Morgan Stanley boosted their price target on shares of Merck & Co., Inc. from $115.00 to $118.00 and gave the stock an equal weight rating in a research note on Friday, October 27th. Five equities research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of Moderate Buy and a consensus price target of $129.68.

Get Our Latest Report on MRK

Merck & Co., Inc. Price Performance

Shares of Merck & Co., Inc. stock opened at $127.47 on Monday. The company has a debt-to-equity ratio of 0.82, a quick ratio of 1.12 and a current ratio of 1.38. The firm’s 50-day simple moving average is $113.66 and its 200-day simple moving average is $108.23. Merck & Co., Inc. has a twelve month low of $99.14 and a twelve month high of $128.06. The firm has a market cap of $323.01 billion, a P/E ratio of 910.50, a price-to-earnings-growth ratio of 1.72 and a beta of 0.38.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last issued its earnings results on Thursday, February 1st. The company reported $0.03 earnings per share for the quarter, beating the consensus estimate of ($0.09) by $0.12. Merck & Co., Inc. had a net margin of 0.61% and a return on equity of 9.07%. The business had revenue of $14.63 billion for the quarter, compared to analyst estimates of $14.49 billion. During the same period in the previous year, the business earned $1.62 EPS. The firm’s revenue was up 5.8% on a year-over-year basis. As a group, research analysts expect that Merck & Co., Inc. will post 8.62 EPS for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, April 5th. Investors of record on Friday, March 15th will be issued a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a yield of 2.42%. The ex-dividend date is Thursday, March 14th. Merck & Co., Inc.’s payout ratio is 2,200.00%.

Insider Activity at Merck & Co., Inc.

In related news, EVP Steven Mizell sold 50,694 shares of the firm’s stock in a transaction on Friday, February 2nd. The shares were sold at an average price of $126.65, for a total value of $6,420,395.10. Following the completion of the transaction, the executive vice president now owns 23,619 shares of the company’s stock, valued at $2,991,346.35. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 0.20% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the business. State Street Corp grew its position in shares of Merck & Co., Inc. by 1.9% in the 2nd quarter. State Street Corp now owns 118,562,086 shares of the company’s stock valued at $13,766,428,000 after acquiring an additional 2,174,829 shares during the period. Wellington Management Group LLP grew its position in shares of Merck & Co., Inc. by 6.7% in the 3rd quarter. Wellington Management Group LLP now owns 82,442,666 shares of the company’s stock valued at $8,487,472,000 after acquiring an additional 5,196,914 shares during the period. Geode Capital Management LLC lifted its stake in shares of Merck & Co., Inc. by 2.9% during the 2nd quarter. Geode Capital Management LLC now owns 52,723,457 shares of the company’s stock worth $6,068,750,000 after buying an additional 1,504,701 shares during the last quarter. Morgan Stanley lifted its stake in shares of Merck & Co., Inc. by 10.6% during the 4th quarter. Morgan Stanley now owns 41,850,081 shares of the company’s stock worth $4,643,267,000 after buying an additional 4,000,816 shares during the last quarter. Finally, Moneta Group Investment Advisors LLC lifted its stake in shares of Merck & Co., Inc. by 103,159.7% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 39,327,490 shares of the company’s stock worth $4,363,385,000 after buying an additional 39,289,404 shares during the last quarter. Institutional investors own 74.59% of the company’s stock.

Merck & Co., Inc. Company Profile

(Get Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.

Further Reading

Analyst Recommendations for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.